FGFR1 Specific Neutra™ Antibody Products
Product listFibroblast growth factor receptor 1 (FGFR1), also known as CEK or FLG, is a membrane protein that is overexpressed in breast carcinomas and normal tissue like plasma and heart. FGFR1 is a receptor for fibroblast growth factors that transduce the signals regulating cell proliferation, differentiation, and migration.
Its Gene ID: 2260, UniProtKB ID: P11362, and OMIM ID: 136350.
Functions of FGFR1 Pathway
Overexpression of FGFR1 could promote the proliferation of lymphoma cells. Via the MYC-KDM2B-EZH2 cascade, FGFR1 regulates the expression of CDKN1C and E2F target genes. Subsequently, FGFR1 maintains the expression level of MYC and provides a proliferative advantage to lymphoma cells.
Fig.1 The role of FGFR1 regulating feedback loop.1
Treatment Strategies Targeting FGFR
The development of FGFR inhibitors is an important for FGFR related cancer studies. Depending on the mechanism of action, FGFR inhibitors can be classified into four types:
- FGF ligand traps that block the activity of FGF-FGFRs interaction.
- Antibody-drug conjugates (ADCs) that comprise a cytotoxic payload linking to an FGFR antibody.
- Antagonistic anti-FGFR antibodies that block the activation of FGF-FGFRs signaling.
- Small molecule tyrosine kinase inhibitors that non-selectively or selectively targets the kinase domain of FGFRs.
Fig.2 Kinds of FGFR inhibitors.2
Creative Biolabs offers several anti-FGFR1 antibodies with high specificity and affinity. These antibodies could be used in cardiovascular disorder and cancer research.
Fig.3 The recombinant human FGFR1 protein was detected using anti-FGFR1 antibody (V3S-0622-YC1620) in ELISA.
Fig.4 The SDS-PAGE analysis of anti-FGR1 antibody (V3S-0622-YC1620).
Fig.5 The SEC-HPLC analysis of anti-FGFR1 antibody (V3S-0622-YC1620).
REFERENCES
- Sircar, Anuvrat, et al. "Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma." Leukemia 37.10 (2023): 2094-2106.
- Ooki, Akira, and Kensei Yamaguchi. "The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration." Gastric Cancer 24.6 (2021): 1169-1183.
